dromlakhani Target mid-normal testosterone range during therapy
STEP 1 — Gather Information
Collect a morning (07:00–11:00) fasting total testosterone (tT) level using a reliable assay (mass spectrometry or standardized immunoassay). Note the laboratory’s reference range for healthy young men (typically ~12–20 nmol/L or 350–600 ng/dL). Also record the testosterone formulation, dose, timing of last dose, and any symptoms.
STEP 2 — Rule In / Rule Out
Is the measured tT within the mid-normal reference range for young men? If yes, maintain current dose and schedule routine monitoring per guideline (e.g., every 3–6 months). If no, proceed to classify direction.
STEP 3 — Classify or Stratify
Classify tT as below mid-normal (low) or above mid-normal (high) relative to the young‑men reference range.
STEP 4 — Decide
If tT is low, increase testosterone dose according to formulation‑specific guidelines (e.g., +50 mg for injectables) and re‑check in 6–12 weeks. If tT is high, decrease dose (e.g., –50 mg for injectables) or extend dosing interval, and re‑check in 6–12 weeks. If symptoms persist despite mid‑normal tT, evaluate adherence, absorption, or concomitant conditions before further dose changes.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on a single outlier tT; confirm with a second measurement if unexpected. Avoid adjusting dose based on trough or peak levels unless the assay timing matches the pharmacokinetic profile of the formulation. Do not target mid‑normal in men >40 years if age‑adjusted lower limits apply per local lab. Ignoring hematocrit >54% or rising PSA may miss polycythemia or prostate safety issues. Do not escalate dose solely for low libido without confirming low tT.
Concrete Clinical Example
A 48‑year‑old man on testosterone cypionate 100 mg every 2 weeks presents for routine follow‑up. Morning tT is 9 nmol/L (lab young‑men range 12–22 nmol/L). Since tT is below mid‑normal, dose is increased to 150 mg every 2 weeks. At 3‑month re‑check, tT is 14 nmol/L (mid‑normal) and symptoms improved; dose is maintained.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), Mohit Khera et al., 2025, https://doi.org/10.1093/sxmrev/qeaf036